Author(s): Lmmen G, Sperling H, Luboldt H, Otto T, Rbben H
Abstract Share this page
Abstract Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.
This article was published in Cancer Chemother Pharmacol
and referenced in Biochemistry & Pharmacology: Open Access